Trials / Completed
CompletedNCT00369616
Efficacy and Safety of Nicotine-Qbeta Vaccine in Smokers
Evaluation of Efficacy and Safety of Nicotine-Qbeta (NicQb) Vaccine Versus Placebo in Healthy Smokers
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 341 (actual)
- Sponsor
- Cytos Biotechnology AG · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- —
Summary
The purpose of this study is to help smokers quitting by vaccinating them with CYT002-NicQb. Upon vaccination, the smoker will generate antibodies directed against free nicotine. The antibodies will bind nicotine and prevent its passage into the brain. The successfully vaccinated smoker will have no reward effect after smoking, thus braking the vicious circle of nicotine addiction.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CYT002-NicQb |
Timeline
- Start date
- 2003-12-01
- Primary completion
- 2005-03-01
- Completion
- 2005-10-01
- First posted
- 2006-08-29
- Last updated
- 2010-11-15
Locations
3 sites across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT00369616. Inclusion in this directory is not an endorsement.